Cargando…

How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension

Essential hypertension is a complex clinical condition, characterized by multiple and concomitant abnormal activation of different regulatory and contra-regulatory pathophysiological mechanisms, leading to sustained increase of blood pressure (BP) levels. Asymptomatic rise of BP may, indeed, promote...

Descripción completa

Detalles Bibliográficos
Autores principales: Tocci, Giuliano, Desideri, Giovambattista, Roca, Elisa, Calcullo, Calogero, Crippa, Massimo, De Luca, Nicola, Gaudio, Giovanni Vincenzo, Lonati, Laura Maria, Orselli, Leo, Scuteri, Angelo, Vulpis, Vito, Acone, Benedetto, Zaninelli, Augusto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842506/
https://www.ncbi.nlm.nih.gov/pubmed/29197935
http://dx.doi.org/10.1007/s40292-017-0242-z
_version_ 1783304908655558656
author Tocci, Giuliano
Desideri, Giovambattista
Roca, Elisa
Calcullo, Calogero
Crippa, Massimo
De Luca, Nicola
Gaudio, Giovanni Vincenzo
Lonati, Laura Maria
Orselli, Leo
Scuteri, Angelo
Vulpis, Vito
Acone, Benedetto
Zaninelli, Augusto
author_facet Tocci, Giuliano
Desideri, Giovambattista
Roca, Elisa
Calcullo, Calogero
Crippa, Massimo
De Luca, Nicola
Gaudio, Giovanni Vincenzo
Lonati, Laura Maria
Orselli, Leo
Scuteri, Angelo
Vulpis, Vito
Acone, Benedetto
Zaninelli, Augusto
author_sort Tocci, Giuliano
collection PubMed
description Essential hypertension is a complex clinical condition, characterized by multiple and concomitant abnormal activation of different regulatory and contra-regulatory pathophysiological mechanisms, leading to sustained increase of blood pressure (BP) levels. Asymptomatic rise of BP may, indeed, promote development and progression of hypertension-related organ damage, which in turn, increases the risk of major cardiovascular and cerebrovascular events. A progressive and independent relationship has been demonstrated between high BP levels and increased cardiovascular risk, even in the high-to-normal range. Conversely, evidence from randomized controlled clinical trials have independently shown that lowering BP to the recommended targets reduces individual cardiovascular risk, thus improving event-free survival and reducing the incidence of hypertension-related cardiovascular events. Despite these benefits, overall rates of BP control remain poor, worldwide. Currently available guidelines support a substantial equivalence amongst various antihypertensive drug classes. However, several studies have also reported clinically relevant differences among antihypertensive drugs, in terms of both BP lowering efficacy and tolerability/safety profile. These differences should be taken into account not only when adopting first-line antihypertensive therapy, but also when titrating or modulating combination therapies, with the aim of achieving effective and sustained BP control. This review will briefly describe evidence supporting the use of dihydropyridinic calcium channel blockers for the clinical management of hypertension, with a particular focus on barnidipine. Indeed, this drug has been demonstrated to be effective, safe and well tolerated in lowering BP levels and in reducing hypertension-related organ damage, thus showing a potential key role for improving the clinical management of hypertension.
format Online
Article
Text
id pubmed-5842506
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-58425062018-03-19 How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension Tocci, Giuliano Desideri, Giovambattista Roca, Elisa Calcullo, Calogero Crippa, Massimo De Luca, Nicola Gaudio, Giovanni Vincenzo Lonati, Laura Maria Orselli, Leo Scuteri, Angelo Vulpis, Vito Acone, Benedetto Zaninelli, Augusto High Blood Press Cardiovasc Prev Review Article Essential hypertension is a complex clinical condition, characterized by multiple and concomitant abnormal activation of different regulatory and contra-regulatory pathophysiological mechanisms, leading to sustained increase of blood pressure (BP) levels. Asymptomatic rise of BP may, indeed, promote development and progression of hypertension-related organ damage, which in turn, increases the risk of major cardiovascular and cerebrovascular events. A progressive and independent relationship has been demonstrated between high BP levels and increased cardiovascular risk, even in the high-to-normal range. Conversely, evidence from randomized controlled clinical trials have independently shown that lowering BP to the recommended targets reduces individual cardiovascular risk, thus improving event-free survival and reducing the incidence of hypertension-related cardiovascular events. Despite these benefits, overall rates of BP control remain poor, worldwide. Currently available guidelines support a substantial equivalence amongst various antihypertensive drug classes. However, several studies have also reported clinically relevant differences among antihypertensive drugs, in terms of both BP lowering efficacy and tolerability/safety profile. These differences should be taken into account not only when adopting first-line antihypertensive therapy, but also when titrating or modulating combination therapies, with the aim of achieving effective and sustained BP control. This review will briefly describe evidence supporting the use of dihydropyridinic calcium channel blockers for the clinical management of hypertension, with a particular focus on barnidipine. Indeed, this drug has been demonstrated to be effective, safe and well tolerated in lowering BP levels and in reducing hypertension-related organ damage, thus showing a potential key role for improving the clinical management of hypertension. Springer International Publishing 2017-12-02 2018 /pmc/articles/PMC5842506/ /pubmed/29197935 http://dx.doi.org/10.1007/s40292-017-0242-z Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review Article
Tocci, Giuliano
Desideri, Giovambattista
Roca, Elisa
Calcullo, Calogero
Crippa, Massimo
De Luca, Nicola
Gaudio, Giovanni Vincenzo
Lonati, Laura Maria
Orselli, Leo
Scuteri, Angelo
Vulpis, Vito
Acone, Benedetto
Zaninelli, Augusto
How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension
title How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension
title_full How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension
title_fullStr How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension
title_full_unstemmed How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension
title_short How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension
title_sort how to improve effectiveness and adherence to antihypertensive drug therapy: central role of dihydropyridinic calcium channel blockers in hypertension
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842506/
https://www.ncbi.nlm.nih.gov/pubmed/29197935
http://dx.doi.org/10.1007/s40292-017-0242-z
work_keys_str_mv AT toccigiuliano howtoimproveeffectivenessandadherencetoantihypertensivedrugtherapycentralroleofdihydropyridiniccalciumchannelblockersinhypertension
AT desiderigiovambattista howtoimproveeffectivenessandadherencetoantihypertensivedrugtherapycentralroleofdihydropyridiniccalciumchannelblockersinhypertension
AT rocaelisa howtoimproveeffectivenessandadherencetoantihypertensivedrugtherapycentralroleofdihydropyridiniccalciumchannelblockersinhypertension
AT calcullocalogero howtoimproveeffectivenessandadherencetoantihypertensivedrugtherapycentralroleofdihydropyridiniccalciumchannelblockersinhypertension
AT crippamassimo howtoimproveeffectivenessandadherencetoantihypertensivedrugtherapycentralroleofdihydropyridiniccalciumchannelblockersinhypertension
AT delucanicola howtoimproveeffectivenessandadherencetoantihypertensivedrugtherapycentralroleofdihydropyridiniccalciumchannelblockersinhypertension
AT gaudiogiovannivincenzo howtoimproveeffectivenessandadherencetoantihypertensivedrugtherapycentralroleofdihydropyridiniccalciumchannelblockersinhypertension
AT lonatilauramaria howtoimproveeffectivenessandadherencetoantihypertensivedrugtherapycentralroleofdihydropyridiniccalciumchannelblockersinhypertension
AT orsellileo howtoimproveeffectivenessandadherencetoantihypertensivedrugtherapycentralroleofdihydropyridiniccalciumchannelblockersinhypertension
AT scuteriangelo howtoimproveeffectivenessandadherencetoantihypertensivedrugtherapycentralroleofdihydropyridiniccalciumchannelblockersinhypertension
AT vulpisvito howtoimproveeffectivenessandadherencetoantihypertensivedrugtherapycentralroleofdihydropyridiniccalciumchannelblockersinhypertension
AT aconebenedetto howtoimproveeffectivenessandadherencetoantihypertensivedrugtherapycentralroleofdihydropyridiniccalciumchannelblockersinhypertension
AT zaninelliaugusto howtoimproveeffectivenessandadherencetoantihypertensivedrugtherapycentralroleofdihydropyridiniccalciumchannelblockersinhypertension
AT howtoimproveeffectivenessandadherencetoantihypertensivedrugtherapycentralroleofdihydropyridiniccalciumchannelblockersinhypertension